Monitoring of Cyclosporine 2-Hour Post-Dose Levels in Heart Transplantation: Improvement in Clinical Outcomes
Authors:
- Diego H. DelgadoDDDiego H. Delgado
- Vivek RaoVRVivek Rao
- Jayne HamelJHJayne Hamel
- Santiago MiriukaSMSantiago Miriuka
- Robert J. CusimanoRCRobert J. Cusimano
- Heather J. RossHRHeather J. Ross
- 1 September 2005
- journal article
- clinical trial
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 24 (9) , 1343-1346
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Impact of cyclosporine 2‐h level and mycophenolate mofetil dose on clinical outcomes inde novoheart transplant patients receiving anti‐thymocyte globulin inductionClinical Transplantation, 2003
- Cyclosporine monitoring based on C2 samplingTransplantation, 2002
- Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2)1Transplantation, 2002
- Neoral monitoring: limitations of trough level monitoring and the potential role of limited sampling strategiesTransplantation Proceedings, 2000
- Neoral use in the cardiac transplant recipientTransplantation Proceedings, 2000
- CLINICAL BENEFIT OF NEORAL DOSE MONITORING WITH CYCLOSPORINE 2-HR POST-DOSE LEVELS COMPARED WITH TROUGH LEVELS IN STABLE HEART TRANSPLANT PATIENTS1Transplantation, 1999
- NEORAL MONITORING BY SIMPLIFIED SPARSE SAMPLING AREA UNDER THE CONCENTRATION-TIME CURVETransplantation, 1999
- PEAK CYCLOSPORINE LEVELS (Cmax) CORRELATE WITH FREEDOM FROM LIVER GRAFT REJECTIONTransplantation, 1999
- COMPARISON OF NEORAL DOSE MONITORING WITH CYCLOSPORINE TROUGH LEVELS VERSUS 2-HR POSTDOSE LEVELS IN STABLE LIVER TRANSPLANT PATIENTS1,2Transplantation, 1998
- A RANDOMIZED, PROSPECTIVE MULTICENTER PHARMACOEPIDEMIOLOGIC STUDY OF CYCLOSPORINE MICROEMULSION IN STABLE RENAL GRAFT RECIPIENTS1,2,3Transplantation, 1996